Table 4.

 Cost effectiveness results for subgroups, based on probabilistic sensitivity analysis

Subgroup	Warfarin cost (£)	Warfarin QALYs	Dabigatran 150 mg bid cost (£)	Dabigatran 150 mg bid QALYs	ICER (£/QALY)	Probability of cost effectiveness*
						At £20 000 per QALY	At £30 000 per QALY
RE-LY population	6480	6.390	9850	6.536	23 082	0.449	0.596
CHADS2 score 2	7412	6.283	10 443	6.433	20 207	0.475	0.615
CHADS2 score ≥3	9912	6.224	12 646	6.396	15 895	0.565	0.683
Centres’ time in therapeutic range ≥65.5%	6247	6.517	9977	6.605	42 386	0.137	0.309
Centres’ time in therapeutic range <65.5%	6617	6.261	9656	6.410	20 396	0.469	0.636
Patients’ time in therapeutic range ≥66.8%	6302	6.401	9850	6.536	26 281	0.393	0.511
Patients’ time in therapeutic range <66.8%	6694	6.360	9850	6.536	17 932	0.519	0.643
Creatinine clearance <30-50 mL/min	7991	6.310	10 788	6.460	18 647	0.501	0.631
Previous stroke or transient ischaemic attack	10 004	6.217	12 787	6.378	17 286	0.525	0.649
Vitamin K antagonist naive	6437	6.396	9792	6.545	22 517	0.446	0.587
Age ≥75 years	4612	4.275	7362	4.429	17 857	0.498	0.635

bid=twice daily; CHADS₂=Congestive heart failure, Hypertension, Age≥75 years, Diabetes mellitus, previous Stroke/transient ischaemic attack; ICER=incremental cost effectiveness ratio; QALY=quality adjusted life year; RE-LY=Randomized Evaluation of Long-Term Anticoagulation Therapy.

*Proportion of simulations in which dabigatran 150 mg twice daily is cost effective versus warfarin.